Analysis of The Mosaic Company’s Q2 2026 10-Q
Filing dated 5 August 2026 for the quarter ended 30 June 2026 · checked against the earnings calls on 25 February, 11 May and 5 August
Where the filing and the story diverge
Mosaic’s story is a temporary sulfur squeeze, one-off charges and disciplined refinancing. The 10-Q shows a dividend funded by borrowing, an inventory build carried on a repurchase facility, and a refinancing that leaves $500M due within a year.
- Three findings: Free cash flow didn’t cover the dividend; The inventory build sits on a repurchase facility; Half the new term loan is due within a year. Each is set out below with the figure, where it sits in the filing and what would close it.
- On the calls. 2 of 3 findings were sidestepped or never asked.
- Management’s record. 1 kept, 1 slipped, 1 changed, 1 missed, 1 reversed on earlier promises.
- What it does not show. Nothing here shows misstatement, an undisclosed liability or a breach of covenants.
- Q2 gross margin
- $214.7M, down 58.6% year on year
- GAAP vs adjusted EPS
- −$0.86 vs +$0.13, bridged by $351M of notable items
- Segment operating result
- Potash +$195M; Phosphate −$104M; Mosaic Fertilizantes −$41M
- Sulfur
- $522 per long ton in Q2; Q3 contracts settled at $705
- Adjusted EBITDA
- $407M vs $566M a year earlier
Three findings, ranked by importance
Each is set out in full below: what the filing shows, the numbers, the evidence and what would close it.
Free cash flow didn’t cover the dividend
H1 free cash flow before $140.7M of dividends. Borrowing filled the gap, and H1 2025 was uncovered too.
H1 operating cash of $271.6M against $677.1M of capex left free cash flow at −$405.5M, before $140.7M of dividends. Borrowing filled the gap. H1 2025 free cash flow was $7.0M against $141.0M of dividends. Covenants are not tight (debt to capitalization max 0.65, interest coverage min 3.0x, both met at June 30), so this is a durability question, not a solvency one.
Borrowing: $502.9M from the new term loan signed June 10 and a net $201.8M more drawn on the inventory financing facility. A further $500M, the 364-day tranche of the same term loan, was drawn on July 14 and is due June 10, 2027.
Evidence“Subsequent to the quarter on July 14, 2026, we borrowed the full $500 million available under the 364-day term loan tranche of the 2026 Term Loan Facility.”Note 9, Financing Arrangements
The inventory build sits on a repurchase facility
Financed inventory up $201.8M in six months, about two thirds of the inventory build.
Inventory rose $305.0M in six months while production was curtailed, led by finished goods (+$353.3M). Inventory financed under the sell-and-repurchase facility rose from $300.2M to $502.0M against a $625M cap. Short-term debt is now essentially commercial paper plus this facility.
Evidence“As of June 30, 2026 and December 31, 2025, we had financed inventory of $502.0 million and $300.2 million, respectively, under this arrangement, which is included in short-term debt on the Condensed Consolidated Balance Sheet.”Note 9, Inventory Financing Arrangement
Half the new term loan is due within a year
Described on the call as terming out short-term debt. Half of the new $1.0B loan is a one-year tranche landing in 2027.
Mosaic signed a $1.0B term loan on June 10 and drew $502.9M in the quarter, then drew the remaining $500M 364-day tranche on July 14, due June 10, 2027. Commercial paper fell from $788.7M to $519.2M as the loan replaced it. In February management said its next maturity was not until 2027 and that paying down debt was the priority; the one-year tranche now lands in that same year. Covenants were met at June 30 (debt to capitalization max 0.65, interest coverage min 3.0x), so this is a refinancing question, not a solvency one.
Evidence“Subsequent to the quarter on July 14, 2026, we borrowed the full $500 million available under the 364-day term loan tranche of the 2026 Term Loan Facility.”Note 9, Financing Arrangements
Other findings, checked and set aside
Each item was tested against the filing. None changes the lead findings above.
| Item | What the filing shows, and why it is not a lead finding |
|---|---|
| Ma’aden mark-to-market | $162M Q2 loss on quoted shares; itemized by management |
| Asset disposals | $238.8M H1 loss; Carlsbad sold; proceeds questions set for the call |
| Structured payables | $480.1M to $353.1M; terms shortened to 180 days |
| Receivable sales | $288.1M sold in H1; read receivable days with care |
| Goodwill | $957.1M Potash goodwill; test as of October 31 |
| Deferred tax assets | Up $394.0M, but deferred tax liabilities rose $193.9M; net moved about $200M. |
What management said about each finding
Checked against the calls on 25 February, 11 May and 5 August.
The CFO confirmed cash from operations will fall about $500M short of capex plus the dividend in 2026, with debt flat in Q3 and lower in Q4. He gave no threshold for when cash covers the dividend again.
“we’re going to be down around $500 million for the year”
Asked about inventory levels, the CFO said physical finished goods were down to 600,000 to 700,000 tons and the trend is down. The $502M repurchase facility was not mentioned, on this call or the two before it.
“This is more a healthier level.”
Not raised by analysts. In prepared remarks the CFO described the loan as replacing and extending very short-term commercial paper. The one-year tranche and its 2027 due date were not mentioned.
“We have a very comfortable short-term liquidity position.”
8 disclosures moved
10-Q Q2 2026 compared with the 10-Q for Q1 2026.
| Status | Disclosure | Before | Now |
|---|---|---|---|
| New | 2026 Term Loan Facility Note 9 | Not present | $1.0B signed June 10; $500M 364-day tranche drawn July 14 |
| New | IRS review of Taquari tax item Note 11 | Accepted into program, March 2026 | IRS review began May 2026, still in process |
| Changed | Tax provision method Note 11 | Estimated annual effective tax rate | Discrete method: annual rate could not be reliably estimated |
| Changed | Inventory financing Note 9 | $401.3M | $502.0M of $625M cap |
| Changed | Finished goods Note 6 | $1,727.7M | $1,940.9M |
| Changed | Commercial paper Note 9 | $788.7M | $519.2M, partly replaced by the term loan |
| Reworded | Structured payables terms Note 9 | 119 to 193 days; $399.4M | 119 to 180 days; $353.1M |
| Removed | Mosaic Fertilizantes description Note 1 | Included “a potash mine” | Reference removed; Potash notes U.S. location sold |
Three of the eight point the same way: more inventory, more inventory financing, and more debt with a short tail. The switch to the discrete tax method is the one most readers will miss.
5 markers for 3 November
Set before the numbers, so the read can be checked afterwards.
| Marker | Now | Gap widens if | Gap closes if | Result |
|---|---|---|---|---|
| 9M free cash flow vs dividends | H1 FCF −$405.5M; dividends $140.7M | FCF still negative, dividend unchanged | FCF covers the dividend | Awaiting |
| Inventory financing | $502.0M of $625M cap | Rises toward the cap | Falls as inventory sells down | Awaiting |
| Phosphate segment | −$104M; sulfur $522 | Loss widens as $705 sulfur arrives | Pricing passes sulfur through | Awaiting |
| Note 11 tax item | $1.4B; IRS review since May | No update | Agreement disclosed, benefit recognized | Awaiting |
| 364-day term loan | $500M due June 10, 2027 | 2027 maturities still stacked | Refinanced into longer debt | Awaiting |
The markers are set before the numbers so the read can be checked afterwards. A widening gap does not by itself mean anything is wrong; it means the reported story and the filing are moving further apart, and the questions for the call become more pressing.
What management said, and what happened
Some misses follow the sulfur shock, which deepened after February when the Persian Gulf conflict hit supply. Capex is a promise kept and beaten.
| Topic | What management said | What happened | Outcome |
|---|---|---|---|
| Cash and the dividend | Feb: Free cash flow after capex expected above the minimum dividend in 2026; priority is paying down debt. May: Aiming to “remain as cash positive as we can”. | About $500M short for the year after capex and the dividend, funded by debt. | Missed |
| Working capital | Feb: $300M to $500M release “highly possible”, stronger in Q2 and Q3. May: More release expected in Q2. | Q2 built inventory by about $200M; most of the release now expected in Q4. | Slipped |
| Debt | Feb: Next maturity not until 2027; priority is debt reduction. | A new $1B term loan, half of it a 364-day tranche due June 2027. | Changed |
| Araxá | Feb: “Araxá will be coming back”, lifting Fertilizantes earnings. May: Idled, with $442M of charges; the decision was “contemplated long before”. | “Advancing the process” to sell it. No timeline or proceeds. | Reversed |
| Capex | Feb: About $1.5B, “really the ceiling”. | Cut to $1.25B in May and $1.2B in August. | Kept |
| Commitment | What they said | Result |
|---|---|---|
| Working capital release in Q3 | $100M to $200M; most of the $300M to $500M in Q4 | Awaiting |
| Net debt in Q3 | Broadly stable, then lower in Q4 | Awaiting |
| Capex in Q3 | Around $300M, then down sharply in Q4 | Awaiting |
| Realised sulfur cost, Q3 | $700 to $710 per ton | Awaiting |
| Realised ammonia cost, Q3 | $610 to $620 per ton | Awaiting |
| DAP price, Q3 | $820 to $840 per ton | Awaiting |
| Fertilizantes | Positive in Q3, below Q2’s $60M EBITDA | Awaiting |
| Free cash flow | Improves in Q3 and again in Q4 | Awaiting |
7 questions, checked against the call
Raised by the 10-Q. To be tested again at Q3 results on 3 November.
Investor relations: Paul Massoud · paul.massoud@mosaicco.com
What this does and does not show
$1.4B tax benefit under IRS review
An unrecognised benefit tied to the Taquari mine sale. If the IRS agrees, Mosaic books up to $1.4B of benefit; if not, nothing was recognised, so there is no write-down. Mostly upside, with no date given.
Not raised by management or analysts on the February, May or August calls.
What would resolve this: An IRS agreement is disclosed and the benefit recognised, or the claim is withdrawn.
Nothing here shows misstatement, an undisclosed liability or a breach of covenants.
Covenants were met at June 30, the revolver is undrawn, and each finding rests on Mosaic’s own disclosures. The findings are about how durable the cash position is, and how fully the story on the calls reflects the filing.
- Nine-month free cash flow covers the dividend
- Inventory financing falls as inventory sells down
- The 364-day tranche is refinanced into longer debt
- Working capital is released in Q3 as promised
- Free cash flow negative again with the dividend unchanged
- Inventory financing rises toward the $625M cap
- 2027 maturities still stacked with no refinancing plan
- Promised Q3 release slips again to Q4
Every figure ties back to the filing
| Form 10-Q, Q2 2026 | Open ↗ |
| Form 10-Q, Q1 2026 | Open ↗ |
| Q2 2026 earnings release | Third-party transcripts |
| Earnings call transcripts, Q4 2025 to Q2 2026 | Third-party transcripts |
Helmledgers reads the full filing, including the notes, and ties every figure to the statement or note it comes from. Findings are ranked by how far the filing departs from the company’s own narrative and how easily they are missed in standard coverage. Earnings calls are read against the filing to record what management answered, sidestepped or left out. This is an accounting read of public SEC filings. It is not an audit opinion and not investment advice.
- Severity
- High: material effect on cash, debt or reported results. Medium: worth tracking, smaller or less certain effect.
- On the call
- Direct answer, Partly answered (topic addressed, figure missing), Sidestepped (raised but not answered) or Not asked.
- Since the read
- Confirmed by a later disclosure, Escalated (grown since), Open (untested) or Missed (not flagged by the read).
- Said versus done
- Kept, Slipped (late), Changed (plan or terms changed), Missed or Reversed.
- Markers
- Measurable checks set before results, each with what would widen or close the gap. Scored after the next results.
- Closes if
- The evidence that would resolve a finding.
Positions: Helmledgers holds no position in MOS. This analysis is an accounting read of public SEC filings and does not constitute investment advice.
This is an accounting read of public SEC filings. It is not an audit opinion and not investment advice.